Abstract
The clinical success of gene therapy is critically dependent on the development of efficient and safe gene delivery reagents, popularly known as “Transfection Vectors”. The transfection vectors commonly used in gene therapy are mainly of two types: viral and non-viral. The efficiencies of viral transfection vectors are, in general, superior to their non-viral counterparts. However, the myriads of potentially adverse immunogenic aftermaths associated with the use of viral vectors are increasingly making the non-viral gene delivery reagents as the vectors of choice. Among the existing arsenal of non-viral gene delivery reagents, the distinct advantanges associated with the use of cationic transfection lipids include their: (a) robust manufacture; (b) ease in handling & preparation techniques; (c) ability to inject large lipid:DNA complexes and (d) low immunogenic response. The present review will highlight the successes, set-backs, challenges and future promises of cationic transfection lipids in non-viral gene therapy.
Keywords: cationic lipids, gene therapy, targeted gene delivery, systemic delivery, lipoplexes
Current Medicinal Chemistry
Title: Cationic Transfection Lipids in Gene Therapy: Successes, Set-backs, Challenges and Promises
Volume: 10 Issue: 14
Author(s): Valluripalli Vinod Kumar, Rajkumar Sunil Singh and Arabinda Chaudhuri
Affiliation:
Keywords: cationic lipids, gene therapy, targeted gene delivery, systemic delivery, lipoplexes
Abstract: The clinical success of gene therapy is critically dependent on the development of efficient and safe gene delivery reagents, popularly known as “Transfection Vectors”. The transfection vectors commonly used in gene therapy are mainly of two types: viral and non-viral. The efficiencies of viral transfection vectors are, in general, superior to their non-viral counterparts. However, the myriads of potentially adverse immunogenic aftermaths associated with the use of viral vectors are increasingly making the non-viral gene delivery reagents as the vectors of choice. Among the existing arsenal of non-viral gene delivery reagents, the distinct advantanges associated with the use of cationic transfection lipids include their: (a) robust manufacture; (b) ease in handling & preparation techniques; (c) ability to inject large lipid:DNA complexes and (d) low immunogenic response. The present review will highlight the successes, set-backs, challenges and future promises of cationic transfection lipids in non-viral gene therapy.
Export Options
About this article
Cite this article as:
Kumar Vinod Valluripalli, Singh Sunil Rajkumar and Chaudhuri Arabinda, Cationic Transfection Lipids in Gene Therapy: Successes, Set-backs, Challenges and Promises, Current Medicinal Chemistry 2003; 10 (14) . https://dx.doi.org/10.2174/0929867033457458
DOI https://dx.doi.org/10.2174/0929867033457458 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mutual Modulation of Femarelle and Vitamin D Analog Activities in Human Derived Female Cultured Osteoblasts
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anti-Inflammatory Approaches that Target the Chemokine Network
Recent Patents on Inflammation & Allergy Drug Discovery The Hypomethylation Agent Bisdemethoxycurcumin Acts on the WIF-1 Promoter, Inhibits the Canonical Wnt Pathway and Induces Apoptosis in Human Non-Small-Cell Lung Cancer
Current Cancer Drug Targets Mesenchymal Stem Cells for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery Meet Our Editorial Board Member
Current Biomarkers (Discontinued) Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Fundamental, Electron Transfer Mechanism by Pyrylium-Type Ions for the Anticancer Drugs 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) and Flavone-8-Acetic Acid (FAA)
Current Medicinal Chemistry - Anti-Cancer Agents Kinases as Upstream Regulators of the HIF System: Their Emerging Potential as Anti-Cancer Drug Targets
Current Pharmaceutical Design Synthesis and Antitumor/Antiviral Evaluation of 6–Thienyl–5–cyano-2–thiouracil Derivatives and Their Thiogalactosides Analogs
Current Organic Synthesis Drug-Resistant Epilepsy and Surgery
Current Neuropharmacology Suppression of Oncoprotein Her-2 and DNA Damage after Treatment with Flavan-3- ol Vitis labrusca Extract
Anti-Cancer Agents in Medicinal Chemistry Newly Recognized Receptors for Vitamin D Metabolites
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ruxolitinib Regulates the Autophagy Machinery in Multiple Myeloma Cells
Anti-Cancer Agents in Medicinal Chemistry Does the Affinity of Cisplatin to B-Vitamins Impair the Therapeutic Effect in the Case of Patients with Lung Cancer-consuming Carrot or Beet Juice?
Anti-Cancer Agents in Medicinal Chemistry Fluorescent Carbon Dots and Nanodiamonds for Biological Imaging: Preparation, Application, Pharmacokinetics and Toxicity
Current Drug Metabolism A Selective, Expeditious and Sustainable Entry en Route to Benzopyrazines and bis-Benzopyrazines
Combinatorial Chemistry & High Throughput Screening Meet Our Regional Editor
Anti-Cancer Agents in Medicinal Chemistry Cruciferous Vegetables as Antioxidative, Chemopreventive and Antineoplasic Functional Foods: Preclinical and Clinical Evidences of Sulforaphane Against Prostate Cancers
Current Pharmaceutical Design Metabolic Effects of Resveratrol in Mammals - a Link Between Improved Insulin Action and Aging
Current Aging Science Combination Therapy of Inhaled Corticosteroids and Long-Acting β2- Adrenergics In Management of Patients with Chronic Obstructive Pulmonary Disease
Current Pharmaceutical Design